Company Description
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder.
Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
| Country | Australia |
| Founded | 1996 |
| IPO Date | Dec 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
Contact Details
Address: 200 Greenhill Road Eastwood Sa, C3 5063 Australia | |
| Phone | 61 8 8150 7400 |
| Website | bionomics.com.au |
Stock Details
| Ticker Symbol | BNOX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $15.45 |
| CIK Code | 0001191070 |
| CUSIP Number | 09063M205 |
| ISIN Number | US09063M2052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President and Director |
| Adrian Hinton BEC, F.C.A. | Financial Controller |
| Timothy M. Cunningham CPA, M.B.A. | Chief Financial Officer |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Consultant Chief Medical Officer of Clinical Neuroscience |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
| Suzanne Irwin B.Com., FCIS | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 15, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 18, 2024 | UPLOAD | Filing |
| Jan 17, 2024 | 20-F/A | Filing |
| Jan 8, 2024 | UPLOAD | Filing |
| Jan 4, 2024 | 6-K | Report of foreign issuer |
| Nov 30, 2023 | 6-K | Report of foreign issuer |